The authors reflect on the development of vaccine for schistosomiasis, a severe parasitic disease. Topics include antigens selectively recognized by IgG1 and IgE serum of Schistosoma haematobium-infected patients, protective immunity to Schistosoma mansoni and S. haematobium infection in humans, and vaccine candidates for schistosomiasis.